201 related articles for article (PubMed ID: 32459193)
21. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; ; Hopper JL; Phillips KA
Med J Aust; 2013 Nov; 199(10):680-3. PubMed ID: 24237098
[TBL] [Abstract][Full Text] [Related]
22. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
Heemskerk-Gerritsen BAM; Jager A; Koppert LB; Obdeijn AI; Collée M; Meijers-Heijboer HEJ; Jenner DJ; Oldenburg HSA; van Engelen K; de Vries J; van Asperen CJ; Devilee P; Blok MJ; Kets CM; Ausems MGEM; Seynaeve C; Rookus MA; Hooning MJ
Breast Cancer Res Treat; 2019 Oct; 177(3):723-733. PubMed ID: 31302855
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
24. Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
Collins JM; Isaacs C
Breast J; 2020 Aug; 26(8):1520-1527. PubMed ID: 32652823
[TBL] [Abstract][Full Text] [Related]
25. BRCA mutation genetic testing implications in the United States.
Bayraktar S; Arun B
Breast; 2017 Feb; 31():224-232. PubMed ID: 27931006
[TBL] [Abstract][Full Text] [Related]
26. Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.
Allué Cabañuz M; Domingo Bretón M; Chóliz Ezquerro J; Arribas Del Amo MD; Güemes Sánchez AT
Cir Esp (Engl Ed); 2020 Dec; 98(10):612-617. PubMed ID: 32505558
[TBL] [Abstract][Full Text] [Related]
27. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: a novel surgical approach to female BRCA-mutation carriers.
Perabò M; Fink V; Günthner-Biller M; von Bodungen V; Friese K; Dian D
Arch Gynecol Obstet; 2014 Jun; 289(6):1325-30. PubMed ID: 24389920
[TBL] [Abstract][Full Text] [Related]
29. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Fatouros M; Baltoyiannis G; Roukos DH
Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
[TBL] [Abstract][Full Text] [Related]
30. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
Giannakeas V; Narod SA
Breast Cancer Res Treat; 2018 Jan; 167(1):263-267. PubMed ID: 28914396
[TBL] [Abstract][Full Text] [Related]
31. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
32. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.
Skytte AB; Gerdes AM; Andersen MK; Sunde L; Brøndum-Nielsen K; Waldstrøm M; Kølvraa S; Crüger D
Clin Genet; 2010 Apr; 77(4):342-9. PubMed ID: 20059483
[TBL] [Abstract][Full Text] [Related]
33. Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
Laitman Y; Michaelson-Cohen R; Levi E; Chen-Shtoyerman R; Reish O; Josefsberg Ben-Yehoshua S; Bernstein-Molho R; Keinan-Boker L; Rosengarten O; Silverman BG; Perri T; Korach J; Mor P; Ephrat Ben-Baruch N; Levy Lahad E; Friedman E;
Cancer; 2019 Mar; 125(5):698-703. PubMed ID: 30489631
[TBL] [Abstract][Full Text] [Related]
34. [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
Menkiszak J; Chudecka-Głaz A; Gronwald J; Bedner R; Cymbaluk-Płoska A; Wezowska M; Zielińska D; Rzepka-Górska I
Ginekol Pol; 2013 Sep; 84(9):758-64. PubMed ID: 24191513
[TBL] [Abstract][Full Text] [Related]
35. Bilateral risk-reducing mastectomy in BRCA mutation carriers: A difficult decision-making.
Franceschini G; Masetti R
Breast J; 2019 May; 25(3):564-565. PubMed ID: 30964221
[No Abstract] [Full Text] [Related]
36. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
Cibula D; Zikan M; Dusek L; Majek O
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1197-207. PubMed ID: 21916573
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with intentions for breast cancer risk management: Does risk group matter?
Conley CC; Agnese DM; Vadaparampil ST; Andersen BL
Psychooncology; 2019 May; 28(5):1119-1126. PubMed ID: 30889627
[TBL] [Abstract][Full Text] [Related]
38. Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies.
Grinstein O; Krug B; Hellmic M; Siedek F; Malter W; Burke C; Schmutzler R; Maintz D; Rhiem K
Surg Oncol; 2019 Jun; 29():126-133. PubMed ID: 31196476
[TBL] [Abstract][Full Text] [Related]
39. Nipple-sparing bilateral prophylactic mastectomy and immediate reconstruction with TiLoop
Casella D; Di Taranto G; Marcasciano M; Sordi S; Kothari A; Kovacs T; Lo Torto F; Cigna E; Ribuffo D; Calabrese C
Breast; 2018 Jun; 39():8-13. PubMed ID: 29455110
[TBL] [Abstract][Full Text] [Related]
40. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
